1. Scrip
  2. >>Business
  3. >>Strategy

Pfizer's Middle Way in VC

 
• By Roger Longman

Pfizer's venture fund, Strategic Investment Group, focuses on commercial "enablers," technologies or services that can give Pfizer new ways of doing business, rather than at new molecules or drug delivery mechanisms. It leaves its drug-focused investments to its business development group.

Corporate venture capital in health care generally tends to be of two types. The first is as a kind of supplement to business development—a way of keeping track of interesting but perhaps fairly long-term pipeline opportunities. The second is as an adjunct to a company's commercial operations—the kinds of investments an R&D-oriented VC wouldn't make.

GlaxoSmithKline PLC 's SR One, Johnson & Johnson 's J&J Development Corp., and Novartis AG 's venture group all fall more or less into the former category,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.